Publications
5600 Results
- Journal / Conference
- Lancet May 14;387(10032):2008-2016; 2016 Mar 8 [Epub ahead of print]
- Year
- 2016
- Research Committee(s)
- Genitourinary
- PMID
- PMID26969090
- PMC
- PMC4878938
- Study Number(s)
- CTSU/E2805
Adjuvant therapy for high-risk kidney cancer: ECOG-ACRIN E2805
- Journal / Conference
- Breast Cancer Research and Treatment Aug;158(3):485-495; 2016 Jul 8 [Epub ahead of print]
- Year
- 2016
- Research Committee(s)
- Breast
- PMID
- PMID27393622
- PMC
- PMC4963434
- Study Number(s)
- S0800
SWOG S0800 (NCI CDR0000636131):Addition of bevacizumab to neoadjuvant nab-paclitaxel with dose–dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
- Journal / Conference
- Breast Cancer Research and Treatment Aug;159(1):87-95; 2016 Jul 30 [Epub ahead of print]
- Year
- 2016
- Research Committee(s)
- Breast
- PMID
- PMID27475087
- PMC
- PMC5021222
- Study Number(s)
- S0622
Phase II studies of two different schedules of dasatinib in bone-metastasis predominant metastatic breast cancer: SWOG S0622
- Journal / Conference
- Journal of Clinical Oncology, Feb 20;34(6):542-549
- Year
- 2016
- Research Committee(s)
- Breast
- PMID
- PMID26527775
- PMC
- PMC4980567
Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib
- Journal / Conference
- International Journal of Radiation Oncology, Biology & Physics, Mar 94(3):493-502
- Year
- 2016
- Research Committee(s)
- Breast
- PMID
- PMID26867878
- PMC
- PMC4752720
Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: results from ACOSOG Z1071 (Alliance)
- Journal / Conference
- Journal of Oncology Practice, Mar;12(3):245-246
- Year
- 2016
- Research Committee(s)
- Genitourinary
- PMID
- PMID26907453
- PMC
- PMC5702793
- Study Number(s)
- S9916
Identifying severe adverse event clusters using the National Cancer Institute's Common Terminology Criteria for Adverse Events
- Journal / Conference
- JAMA Oncology, Apr 1;2(4):425-426; 2016 Feb 11 [Epub ahead of print]
- Year
- 2016
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID26868102
- PMC
- PMC n/a [opinion article]
Addressing skyrocketing cancer drug prices comes with tradeoffs: pick your poison. [Opinion]
- Journal / Conference
- Cancer Apr 1;122(7):988-999
- Year
- 2016
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID26849003
- PMC
- PMC n/a - review article
Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future [Review]
- Journal / Conference
- Journal of Clinical Oncology 34, 2016 (suppl; abstr 10001); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation
- Year
- 2016
- Research Committee(s)
- Breast, Genitourinary, Gynecologic, Head and Neck, and Lung
- Study Number(s)
- S0003, S0007, S0009, S0012, S0022, S0023, S0027, S0028, S0029, S0032, S0102, S0219, S0221, S0329, S0421, S0536, S0819, S9712, S9900, S9902, S9912, S9914, S9916
Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials
- Journal / Conference
- British Journal of Haematology, Feb;172(3):384-391
- Year
- 2016
- Research Committee(s)
- Leukemia
- PMID
- PMID26577691
- PMC
- PMC4794257
- Study Number(s)
- E1905